Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: An observational single-centre study

Gunaldi M., Duman B. B., Afsar C. U., PAYDAŞ S., Erkisi M., KARA İ. O., ...Daha Fazla

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.22, sa.2, ss.242-247, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 22 Sayı: 2
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1177/1078155214567162
  • Dergi Adı: JOURNAL OF ONCOLOGY PHARMACY PRACTICE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.242-247
  • Anahtar Kelimeler: Trastuzumab, breast cancer, cardiotoxicity, onco-pharmacology, risk factors, ADJUVANT TRASTUZUMAB, CARDIAC DYSFUNCTION, THERAPY, DOXORUBICIN
  • Çukurova Üniversitesi Adresli: Evet

Özet

Background: Trastuzumab is a recombinant humanized monoclonal antibody used to treat human epidermal growth factor receptor 2 positive breast cancer, with recognized associated cardiotoxicity. In this retrospective observational study, we investigated associated cardiotoxicity on clinical outcomes using trastuzumab in women referred to our clinic.